💊 Thuốc A-Z 🧬 Đích tác dụng 🛠 Công cụ 📚 Hướng dẫn
Tất cả thuốc Phân loại thuốc Lĩnh vực điều trị Tác dụng phụ
Hướng dẫn Từ điển thuật ngữ Dòng thời gian
So sánh Hành trình của thuốc Các họ thuốc
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Baricitinib

CHEMBL2105759 Phase 4 Đã phê duyệt Small molecule
Half-Life
12 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
371.4 g/mol
LogP
-0.5
Phase
4

A JAK1/JAK2 inhibitor that blocks the intracellular signaling pathways that drive inflammation in conditions such as rheumatoid arthritis and atopic dermatitis. It is taken by mouth once daily.

Khối lượng phân tử

371,4170 g/mol

LogP

-0,50

TPSA

129,00 Ų

Lipinski RO5

Đạt

Lĩnh vực điều trị

Pain Management Rheumatoid Arthritis Infectious Disease Psoriasis Systemic Lupus Erythematosus Chronic Kidney Disease Lymphoma Type 2 Diabetes Major Depressive Disorder Atopic Dermatitis Gout Chronic Pain HIV/AIDS Leukemia

Phân loại thuốc

L — L - Antineoplastic and Immunomodulating Agents

Cơ chế tác dụng

Selective JAK1 and JAK2 inhibitor blocking cytokine signaling involved in inflammation.

Pharmacokinetics (PK)

Half-Life 12 hours

Pharmacodynamics (PD)

Cơ chế

Selective JAK1 and JAK2 inhibitor blocking cytokine signaling involved in inflammation.

Cấu trúc 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1

                

                

                
                

                    
InChI

                    
InChI=1S/C16H17N7O2S/c1-2-26(24,25)22-9-16(10-22,4-5-17)23-8-12(7-21-23)14-13-3-6-18-15(13)20-11-19-14/h3,6-8,11H,2,4,9-10H2,1H3,(H,18,19,20)

                

                

                

                    
                    

                        
Molecular Formula

                        
C16H17N7O2S

                    

                    
                    

                        
HBD / HBA

                        
1 / 7

                    

                    
                    

                        
Liên kết có thể quay

                        
5

                    

                    
                    
                    

                        
Nguyên tử nặng

                        
26

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Câu hỏi thường gặp

                

                    
                    

                        
                        

                            
A JAK1/JAK2 inhibitor that blocks the intracellular signaling pathways that drive inflammation in conditions such as rheumatoid arthritis and atopic dermatitis. It is taken by mouth once daily.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Selective JAK1 and JAK2 inhibitor blocking cytokine signaling involved in inflammation.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Baricitinib: Half-life: 12 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Baricitinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Methotrexate
                            Small molecule
                        
                        
                        
                            Tamoxifen
                            Small molecule
                        
                        
                        
                            Cyclosporine
                            Protein
                        
                        
                        
                            Tacrolimus
                            Small molecule
                        
                        
                    

                

                

                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL2105759.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 44205240.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Tuyên bố miễn trách y tế

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.